R ecent advances in nanoscience and biomedicine have expanded our ability to design and construct multifunctional nanoparticles that combine targeting, therapeutic, and diagnostic functions within a single nanoscale complex. The theranostic capabilities of gold nanoshells, spherical nanoparticles with silica cores and gold shells, have attracted tremendous attention over the past decade as nanoshells have emerged as a promising tool for cancer therapy and bioimaging enhancement.
Introduction
Despite prodigious advances in our understanding of the disease, cancer remains one of the leading causes of death in the United States. More than 1.5 million new cases of cancer were projected for 2010, with an anticipated mortality rate of 37%. 1 and therapeutics at the cellular and molecular level. 4, 5 Nanoparticles provide several potential advantages over conventional agents, including extension of circulating half-life, passive accumulation at tumor sites due to the enhanced permeability and retention (EPR) effect, active targeting of cancer cells, reduced toxicity, and integration of multiple diverse functions in a single complex. 6, 7 The past two decades have witnessed a rapid increase in the design of nanoparticle-based contrast agents 8 and therapeutic actuators. 9 Recently, these two functionalities have begun to be combined within a single nanoscale complex, resulting in the development of "theranostic" nanocomplexes, which are emerging as an alternative to independently administered diagnostic probes and traditional cancer therapy strategies. 10À17 Theranostic probes are a class of agents that can simultaneously deliver diagnostic and therapeutic functions, enabling detection and treatment of diseases in a single procedure. Interest in theranostics is rapidly increasing due to the versatility of nanoparticlebased approaches. Since multiple types of molecules can be incorporated onto a single nanoparticle surface, the same nanoscale complex can perform multiple functions. Of particular importance is the combination of targeting species with contrast agents that enable tracking of the theranostic complex. 18, 19 This specific combination of functions can provide valuable biodistribution information, opportunities to study the therapeutic mechanism, and strategies for improving therapeutic efficacy, all in vivo. Theranostic nanoparticles can be readily fabricated since the synthetic procedure is typically a combination of well-established chemistries originally developed solely for imaging or 21 The optical absorption of AuNSs can be tuned to the nearinfrared spectral range known as the "water window" (690À 900 nm), where tissue is maximally transparent, by varying the relative size of the core and shell. 22 AuNSs resonant in the near-infrared can be strong absorbers or scatterers, depending on particle size, enabling both bioimaging and photothermal ablation. 23, 24 Tuning the nanoshell resonance to the emission frequency of a weak NIR fluorophore can provide fluorescence enhancement. 25, 26 The bright nanoshellÀfluorophore conjugates can be employed for combined fluorescence-based imaging and photothermal ablation. 27À29 The plasmon-based optical properties of AuNSs also enable the efficient release of antisense DNA oligonucleotides conjugated to the complex, providing a light-triggerable, nonviral vector for gene therapy. 30, 31 In our previous Account, we focused on AuNSs as therapeutic actuators and their corresponding clinical impact. 21 In this Account, we emphasize the progress of AuNS-based complexes for theranostic applications, which combine fluorescence imaging, MRI, and photothermal therapy, as well as gene therapy.
Photothermal Properties
Nanoshells were the first nanoparticle used to demonstrate photothermal cancer therapy: 32 the transition of this approach to clinical trials is currently underway. 21 The therapeutic response of AuNSs results from their ability to absorb light resonant with the nanoshell plasmon energy and dissipate the light energy thermally. The physical process underlying the photothermal characteristics of noble metal nanoparticles has been studied dynamically. 33 When
AuNSs are excited with resonant light, photoexcitation of the electron gas results in rapid nonequilibrium heating. The initial electronic excitation is followed by subpicosecond relaxation, by means of electronÀelectron scattering, giving rise to a rapid increase in the surface temperature of the metal. This initial rapid heating is followed by cooling to equilibrium by energy exchange between the electrons and the lattice. At very fast rates of energy dissipation (a few picoseconds) relative to lattice cooling, intense photothermal heating can result in the melting or reshaping of the nanostructure, changing its optical characteristics irreversibly. 33 In the first several hundred picoseconds following excitation, the lattice cools via phonons, resulting in heating of the medium directly surrounding the nanostructure. When AuNSs in a cellular medium are illuminated, a large temperature difference between the hot AuNS surface and the cooler surrounding biological medium occurs. This abrupt local temperature increase is responsible for cell death.
Fluorescence Enhancement
When illuminated with resonant light, nanoshell plasmons decay nonradiatively, resulting in absorption, and radiatively, resulting in light scattering. These characteristics can modify the emission properties of fluorophores in their proximity. 25, 26 Fluorescence enhancement or quenching of fluorophores by nearby noble metal surfaces has been known since the pioneering work of Drexhage. 34 The metalÀfluorophore interaction results from (i) modification of the electromagnetic field and (ii) the photonic mode density near the fluorophores. For small metalÀfluorophore distances (e4 nm), the damping of molecular oscillators by processes such as electron tunneling between the metal and the fluorophore and image interactions between the two systems typically lead to strong quenching of the molecular fluorescence. The increase in nonradiative decay rate for short fluorophoreÀmetal distances depends on the inverse cube of the moleculeÀsurface separation. 35 However, for larger metalÀfluorophore distances, an increase in the fluorescence intensity can occur, resulting primarily from a combination of enhanced absorption of the fluorophore by the metal's surface field and an enhanced radiative decay rate of the fluorophore. Both these processes can increase the quantum yield of the fluorophore. At a noble metal nanoparticle (nanoantenna) surface, emission can be further enhanced by coupling of the fluorescence emission to the far field by scattering. 25 Quantum yield of the near-infrared fluorophore indocyanine green (ICG), a U.S. Food and Drug Administration (FDA) approved fluorophore, was enhanced from 1% to ∼80% by placing it near a AuNS surface. These bright nanoshellÀfluorophore conjugates have been used for enhancing sensitivities in fluorescence imaging in vitro and in vivo.
27,29
Optical Imaging and Therapy
The ability of nanoshells to convert absorbed light to heat has been successfully exploited for photothermal therapy. 23, 36 AuNSs designed to scatter light in the NIR physiological "water window" have also been employed as contrast agents for dark-field scattering, 37 photoacoustic imaging, 38 and optical coherence tomography (OCT).
24
AuNSs of intermediate size (60 nm core radius, 10À12 nm shell thickness) can both absorb and scatter light at 800 nm and can therefore serve as imaging contrast agents and photothermal actuators. AuNSs bound to anti-HER2 antibodies have been demonstrated for dark-field imaging and therapy of SKBR3 breast carcinoma cells. 37 AuNSs have also been examined in vivo for enhancement of optical coherence tomography (OCT) and for inducing photothermal cell death. 24 In combining these two functions, it is important to note that the light intensities typically used for imaging are far below those used to induce photothermal effects. For in vivo studies, AuNSs were encapsulated with a layer of thiolated poly(ethylene glycol) (PEG-SH) molecules, where the thiol group is bound to the Au surface. The poly(ethylene glycol) (PEG) functional group, a nontoxic polymer, is known to reduce nanoparticle aggregation, reduce nonspecific binding in vivo and significantly extend blood-circulation time. PEG-conjugated AuNSs were injected intravenously into the tail vein of tumor-bearing mice and allowed to accumulate passively in the tumor. Phosphate-buffered saline (PBS) solution was injected in control mice. Twenty hours postinjection, tumors were imaged with a commercial OCT system by placing the imaging probe directly above the tumor, in contact with the skin. Representative OCT images of normal tissue and tumor tissue with both PBS and AuNSs are shown in Figure 1 . The enhanced brightness (Figure 1d ) clearly demonstrates that AuNSs provide significant contrast for OCT imaging in vivo. Following imaging, tumors were irradiated using a near-infrared laser (808 nm, 4 W/cm 2 , 5 mm spot size) for 3 min. Tumor size and animal survival were studied for 7 weeks post-treatment. The tumor sizes on the day of treatment and 12 days post-treatment are shown (Figure 1e ). The tumors in all but two mice treated with AuNSs and laser irradiation had completely degenerated in 21 days. The median survival of mice injected with PBS followed by laser treatment was 14 days and that of the untreated control group was 10 days. Median survival time of AuNS treated mice was longer than 7 weeks, with a longterm survival of 83%.
Multimodal Imaging and Therapy
Nanoshell-based complexes have recently been expanded to include two diagnostic capabilities, MRI and near-infrared fluorescence imaging, in addition to photothermal therapy. 27, 28 Nanocomplexes were constructed by encapsulating AuNSs in a silica epilayer doped with ∼10 nm iron oxide (Fe 3 O 4 ) nanoparticles and ICG (Figure 2a) . The nanocomplexes were subsequently functionalized with streptavidin and conjugated with biotinylated antibodies, then passivated with thiolated PEG to reduce nonspecific binding. MR relaxivity, r 2 , of the nanocomplexes (Figure 2b ) was observed to be significantly higher than that of AMI-25 and Resovist, two FDA-approved with MDAMB231 tumors, with a maximum accumulation of the nanocomplex at 24 h. Analogous to fluorescence imaging, MR images also show a higher accumulation of nanocomplexes in HER2-overexpressing tumors relative to the control. The discrepancy observed between MRI and fluorescence imaging results is attributed, in part, to the lower sensitivity and signal-to-noise ratio of MRI. However, MRI offers high spatial resolution providing complete anatomical structural information of tumors relative to optical approaches. Fluorescence imaging offers exceptional sensitivity; however due to the surface-weighted characteristics of this modality, nanocomplexes accumulated near the tumor surface are imaged preferentially. Nanocomplexes take longer to accumulate within the tumor core relative to the peripheral vasculature, contributing to the dissimilarity between the MRI and fluorescence analysis. Integrating these two complementary techniques within a single nanocomplex could be quite advantageous in establishing more accurate, and ultimately quantitative, imaging methods.
The individual organs of the mice were analyzed to evaluate the biodistribution of the nanocomplexes at 72 h postinjection. Near-infrared fluorescence images of tissues (Figure 4c ) retrieved from MDAMB231 and BT474AZ mice show maximum accumulation in the tumor relative to other tissues. A surface-averaged fluorescence intensity analysis, where fluorescence intensity was divided by the surface area of each tissue (Figure 4d ) correlate well with the images. The Au content in each tissue was also measured using inductively coupled plasma-mass spectrometry (ICP-MS), to independently verify, as quantitatively as possible, nanocomplex distribution in the tissues. The Au distribution (μg) per mass of tissue (g) for both BT474AZ and MDAMB231 mice (Figure 4e) correlates well with the measured fluorescence intensities, albeit with some variations. In both tumor types, the tumors and liver have significant Au content. Since the liver is inherently highly absorbing at NIR wavelengths, nanocomplexes deeper in the liver may not be observable by fluorescence but may be accurately measured by ICP-MS. These comparative studies illustrate the ability of nanocomplexes to target breast cancer cells, enhance images of the binding event and specific location on the cell surface, and deliver a therapeutic heating dose upon photothermal actuation.
Gene Therapy
Gene therapy is the process of inserting a small DNA or RNA sequence to modify the expression of certain specific proteins associated with disease. Two of the most promising gene therapies are antisense DNA and short interfering RNA (si-RNA) therapy. Both target messenger RNA (mRNA), the intermediary between the DNA and the protein, to selectively inhibit the expression of an unwanted protein (downregulation). In antisense therapy, short ss-DNA strands (15À30 bases) hybridize to the mRNA, blocking production of the diseasecausing protein and activating the enzyme RNase H that degrades the mRNA. si-RNA therapy consists of delivering short ds-RNA sequences (19À21 bases) to the cells that first bind to RNA-induced silencing complex (RISC), an enzyme located within cells. This facilitates the binding of siRNA to mRNA, cleaving the mRNA and leading to downregulation of the undesired protein. While gene therapy holds tremendous promise in addressing a wide range of diseases, a major challenge is the delivery of oligonucleotide sequences into the cellular environment. Early experiments using viruses for gene delivery resulted in fatalities in clinical trials, greatly slowing the development of this approach. One of the most promising alternative technologies for gene delivery is the use of AuNPs as delivery vehicles. 40, 41 A variety of AuNPs of various shapes and sizes have been used in initial demonstrations of protein downregulation. AuNSs meet many of the desired characteristics for gene delivery: no immunogenic response, steric protection of bound DNA/ RNA against nucleases, good cellular uptake, and facile gold surface chemistry. 30 The plasmonic properties of AuNSs that assist in the photothermal ablation of solid tumors maybe used to light-trigger the release of short DNA strands conjugated to the surface of AuNSs. The light-triggered release of the DNA from AuNSs also allows precise temporal control over DNA/RNA release, potentially enabling a more detailed understanding of the kinetics of protein downregulation.
Light-triggered release of antisense DNA from AuNSs was recently demonstrated. 30 The complementary strand to the antisense sequence was modified with a thiol moiety that allowed for facile conjugation of the sense strand to the AuNS surface ( Figure 5 ). The antisense strand (red) is hybridized to the thiolated complementary sense sequence (green), then attached to the Au to form a DNA monolayer on the AuNS surface. Gel electrophoresis was used to quantify the released ss-DNA in solution. A 3% agarose gel was used to separate the ss-DNA from the nanoshellÀDNA complex. Antisense DNA release from AuNSs by heating the solution conventionally and by plasmon-resonant NIR light was compared. DNA melting curves for a 20-base DNA oligonucleotide (TATGATCTGTCACAGCTTGA) released by heating the nanoshellÀDNA solution in a water bath (Figure 5c ) and by illuminating the solution with a NIR laser (Figure 5d ) are shown. The maximum of the first derivative of the melting profile corresponds to the melting temperature (T c ) at which 50% of the DNA is released. For the antisense oligonucleotide used, the release temperature was found to be 37°C, while for NIR light release, T c occurred at a solution ambient temperature of 27°C. Several oligomers of varying length and composition were studied. Similar dramatic lowering of the DNA melting temperature for the resonant light-induced release was observed consistently for various lengths and compositions of DNA (Figure 5b) . 30 DNA release always occurred prior to any significant heating of the AuNS solution: this is an essential regime for biological applications, ensuring that DNA can be released using light without the induction of hyperthermic cell death. 42 The coverage was determined to be 6400 ds-DNA/nanoshell, corresponding to a concentration of 14.6 pmol/cm 2 . In the two experiments, 30 ∼90% of the ss-DNA was released in the thermal release experiment, while ∼50% was released using light at near-ambient temperature.
In addition to the release of antisense DNA, the ds-DNAÀ AuNS complex serves as an effective host for the directed delivery of other small molecules into cells. Molecules may associate with ds-DNA by intercalating between the grooves of the ds-DNA. 43 The light triggered release of the antisense-DNA and delivery of small molecules into cells has been recently demonstrated using DAPI molecules with ds-DNA bound to AuNSs. DAPI is a water-soluble blue fluorescent dye that binds reversibly in the minor groove of ds-DNA and is frequently used to stain cells to visualize their nuclei. ds-DNAÀnanoshell complexes were loaded with DAPI by incubating DAPI solution with ds-DNAÀnanoshell complexes and then incubated with H1299 lung cancer cells to allow uptake of the complexes. 31 Upon illumination with an 800 nm CW laser (1 W/cm 2 , 5 min), corresponding to the peak resonant wavelength of the AuNS complexes, the ds-DNA dehybridizes and the ss-DNA and the DAPI molecules are released within the cells. Subsequent to release, the DAPI diffuses through the cytoplasm and into the cell nucleus, where it preferentially binds to and stains the nuclear DNA.
To quantify the fluorescence of the DAPI bound to just the nuclear DNA without measuring the fluorescence from the cytoplasm of the cell, the cell nuclei were isolated, and the DAPI fluorescence of the nuclei was measured by flow cytometry. The normalized histograms of DAPI fluorescence intensity versus number of nuclei from H1299 cells incubated with ds-DNAÀAuNSÀDAPI before and after laser treatment are shown (Figure 6a ). After laser treatment, the fluorescence intensity of the nuclei increased significantly. An ∼33% increase in fluorescence intensity is observed. Epifluorescence images of H1299 cells incubated with AuNSÀdsDNAÀDAPI before (Figure 6c , left) and after (Figure 6c, right) laser treatment clearly show a marked increase in DAPI fluorescence. A control experiment consisting of H1299 cells incubated with DAPI only (no AuNSs) was conducted (Figure 6b ). The cells were irradiated with the NIR laser under conditions identical to the previous experiment. The mean DAPI fluorescence intensity did not significantly increase after laser irradiation. Many classes of molecules can intercalate into ds-DNA, including antibiotics, steroids, and chemotherapeutic molecules, making this ds-DNAÀAuNS platform an extremely promising and highly general controlled intracellular delivery mechanism.
Summary and Future Perspectives
This Account summarizes the progress of nanoshells from standalone photothermal actuators to multifunctional theranostic nanocomplexes with targeting, contrast enhancement for diagnostics, photothermal therapy, and gene therapy capabilities. Since nanoshell-based photothermal therapy has already transitioned to clinical trials, we envision that the theranostic possibilities of nanoshells will also see significant progress within the next decade for applications in vitro, in vivo, and in adjuvant settings. 44 Theranostic nanoparticles as delivery vectors should ultimately allow us to simultaneously visualize and deliver therapeutics to metastatic cancer sites. 23 The mortality rate of patients with macroscopic metastatic disease continues to be significantly high due to acquired resistance. Furthermore, theranostic nanoparticles, which combine multiple imaging modalities, may ultimately enable us to monitor processes, therapeutic mechanisms, and outcomes in disease sites that have remained largely inaccessible, for example, the brain. Theranostics is truly emblematic of the evolution of multidisciplinary nanoscience, as a gradual convergence of multiple disciplines including chemistry, material science, electromagnetics, biology, medical physics, and oncology. We can predict high-impact advances in this field as researchers pioneer approaches to develop nanoscale platforms with multiple functionalities. However, several aspects must be evaluated before theranostics can advance, including nanoparticle size and surface characteristics, appropriate dosage of both diagnostic and therapeutic functions, toxicity and biocompatibility as controlled by the surface chemistry of the nanocomplexes, the detailed tracking of theranostic nanoparticles and their interactions in vivo. Pursuing these important aspects will enable theranostics to transition from the laboratory to clinical settings. 
